Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive … Read more
Senzime AB (SEZI) - Net Assets
Latest net assets as of December 2025: Skr304.46 Million SEK
Based on the latest financial reports, Senzime AB (SEZI) has net assets worth Skr304.46 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr369.81 Million) and total liabilities (Skr65.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr304.46 Million |
| % of Total Assets | 82.33% |
| Annual Growth Rate | 21.03% |
| 5-Year Change | 102.19% |
| 10-Year Change | 130.88% |
| Growth Volatility | 46.75 |
Senzime AB - Net Assets Trend (2005–2025)
This chart illustrates how Senzime AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Senzime AB (2005–2025)
The table below shows the annual net assets of Senzime AB from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr304.46 Million | -11.97% |
| 2024-12-31 | Skr345.86 Million | -7.89% |
| 2023-12-31 | Skr375.48 Million | +43.36% |
| 2022-12-31 | Skr261.90 Million | +73.93% |
| 2021-12-31 | Skr150.58 Million | -34.91% |
| 2020-12-31 | Skr231.35 Million | +41.33% |
| 2019-12-31 | Skr163.69 Million | -2.22% |
| 2018-12-31 | Skr167.41 Million | +19.19% |
| 2017-12-31 | Skr140.46 Million | +6.51% |
| 2016-12-31 | Skr131.87 Million | +187.86% |
| 2015-12-31 | Skr45.81 Million | +3.92% |
| 2014-12-31 | Skr44.08 Million | +17.67% |
| 2013-12-31 | Skr37.46 Million | +17.12% |
| 2012-12-31 | Skr31.99 Million | +14.79% |
| 2011-12-31 | Skr27.87 Million | +27.25% |
| 2010-12-31 | Skr21.90 Million | +31.80% |
| 2009-12-31 | Skr16.61 Million | -9.39% |
| 2008-12-31 | Skr18.34 Million | +96.51% |
| 2007-12-31 | Skr9.33 Million | +23.62% |
| 2006-12-31 | Skr7.55 Million | +12.74% |
| 2005-12-31 | Skr6.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Senzime AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 77507600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr19.65 Million | 6.45% |
| Other Comprehensive Income | Skr-374.00K | -0.12% |
| Other Components | Skr1.06 Billion | 348.24% |
| Total Equity | Skr304.46 Million | 100.00% |
Senzime AB Competitors by Market Cap
The table below lists competitors of Senzime AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scana ASA
OL:SCANA
|
$49.95 Million |
|
Pulse Seismic Inc
OTCQX:PLSDF
|
$49.96 Million |
|
King’s Town Construction Co Ltd
TW:2524
|
$49.96 Million |
|
Marie Brizard Wine & Spirits
PA:MBWS
|
$49.99 Million |
|
Selena FM S.A.
WAR:SEL
|
$49.87 Million |
|
Asian Sea Corporation Public Company Limited
BK:ASIAN
|
$49.87 Million |
|
Emak S.p.A
F:EK4
|
$49.85 Million |
|
United Purification Technology Co., Ltd.
TWO:6977
|
$49.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Senzime AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 345,857,000 to 304,461,000, a change of -41,396,000 (-12.0%).
- Net loss of 137,419,000 reduced equity.
- Share repurchases of 104,243,000 reduced equity.
- New share issuances of 104,243,000 increased equity.
- Other comprehensive income decreased equity by 9,476,000.
- Other factors increased equity by 105,499,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-137.42 Million | -45.14% |
| Share Repurchases | Skr104.24 Million | -34.24% |
| Share Issuances | Skr104.24 Million | +34.24% |
| Other Comprehensive Income | Skr-9.48 Million | -3.11% |
| Other Changes | Skr105.50 Million | +34.65% |
| Total Change | Skr- | -11.97% |
Book Value vs Market Value Analysis
This analysis compares Senzime AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.42x to 2.11x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | Skr3.07 | Skr4.36 | x |
| 2010-12-31 | Skr2.97 | Skr4.36 | x |
| 2011-12-31 | Skr3.03 | Skr4.36 | x |
| 2012-12-31 | Skr2.78 | Skr4.36 | x |
| 2013-12-31 | Skr2.87 | Skr4.36 | x |
| 2014-12-31 | Skr3.03 | Skr4.36 | x |
| 2015-12-31 | Skr2.97 | Skr4.36 | x |
| 2016-12-31 | Skr4.66 | Skr4.36 | x |
| 2017-12-31 | Skr3.51 | Skr4.36 | x |
| 2018-12-31 | Skr3.74 | Skr4.36 | x |
| 2019-12-31 | Skr3.22 | Skr4.36 | x |
| 2020-12-31 | Skr4.06 | Skr4.36 | x |
| 2021-12-31 | Skr2.38 | Skr4.36 | x |
| 2022-12-31 | Skr3.88 | Skr4.36 | x |
| 2023-12-31 | Skr4.07 | Skr4.36 | x |
| 2024-12-31 | Skr2.83 | Skr4.36 | x |
| 2025-12-31 | Skr2.07 | Skr4.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Senzime AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -132.11%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.21x
- Recent ROE (-45.14%) is below the historical average (-22.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -10.36% | -102.10% | 0.08x | 1.27x | Skr-3.38 Million |
| 2010 | -10.75% | -137.70% | 0.07x | 1.18x | Skr-4.54 Million |
| 2011 | -7.54% | -115.59% | 0.06x | 1.14x | Skr-4.89 Million |
| 2012 | -13.73% | -1472.30% | 0.01x | 1.04x | Skr-7.59 Million |
| 2013 | -14.94% | -453.26% | 0.03x | 1.03x | Skr-9.34 Million |
| 2014 | -14.05% | -1144.16% | 0.01x | 1.05x | Skr-10.60 Million |
| 2015 | -16.55% | -4966.72% | 0.00x | 1.04x | Skr-12.16 Million |
| 2016 | -7.14% | -578.13% | 0.01x | 1.19x | Skr-22.60 Million |
| 2017 | -9.27% | -6892.59% | 0.00x | 1.18x | Skr-27.07 Million |
| 2018 | -15.30% | -797.17% | 0.02x | 1.18x | Skr-42.36 Million |
| 2019 | -20.57% | -501.79% | 0.04x | 1.15x | Skr-50.04 Million |
| 2020 | -20.51% | -508.14% | 0.04x | 1.12x | Skr-70.58 Million |
| 2021 | -54.55% | -748.11% | 0.06x | 1.16x | Skr-97.20 Million |
| 2022 | -50.67% | -945.56% | 0.04x | 1.23x | Skr-158.89 Million |
| 2023 | -35.73% | -375.20% | 0.08x | 1.15x | Skr-171.70 Million |
| 2024 | -34.33% | -203.03% | 0.14x | 1.23x | Skr-153.31 Million |
| 2025 | -45.14% | -132.11% | 0.28x | 1.21x | Skr-167.87 Million |
Industry Comparison
This section compares Senzime AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Senzime AB (SEZI) | Skr304.46 Million | -10.36% | 0.21x | $49.92 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |